Introduction
Nephrotic syndrome (NS) is a chronic kidney disease that is defined by significant proteinuria (>40 mg/m 2 /h), with resulting hypoalbuminemia, which causes edema (1). NS constitutes the second most frequent cause of end-stage kidney disease (ESKD) in children (2, 3) . While most children with NS have steroid-sensitive NS, approximately 10%-20% of children and 40% of adults with NS do not achieve sustained remission after glucocorticoid therapy and additional immunosuppressive therapy and enter into ESKD (1). These cases of steroid-resistant NS (SRNS) manifest histologically as focal segmental glomerulosclerosis (FSGS) (4) .
Recent discoveries of the single-gene causes of NS have significantly increased our understanding of glomerular filtration barrier physiology and of pathogenic mechanisms of NS (1). To date, more than 9 recessive genes that cause NS if mutated have been identified (5, 6) . Overall, these genes account for up to approximately 66% of NS that starts within the first year of life (2) . However, monogenic causes of a significant proportion of childhood-or adult-onset NS are still molecularly unsolved. Moreover, recently identified genes are very rare, being mutated in only one family out of hundreds (7) . To overcome the limitations posed by the rarity of genes when identifying genes associated with NS, we established a strategy of combining homozygosity mapping (HM) with whole-exome resequencing (WER) (8, 9) . Here, we applied this approach to sibling cases of childhood-onset NS and thereby identified mutations of aarF domain containing kinase 4 (ADCK4) as a single-gene cause of SRNS.
Results
Mutations in ADCK4 cause SRNS. To identify further single-gene causes of SRNS, we performed HM followed by WER in a group of individuals with histology that revealed FSGS ( Figure 1, A and B) . In a family (A2338) of Arab origin, 2 siblings had early-onset SRNS and renal histology that revealed glomerulosclerosis ( Figure 1A) . HM in both affected siblings yielded 5 regions of homozygosity by descent with a cumulative genomic length of approximately 115 Mb, none of which coincided with any of 7 common recessive causes of SRNS ( Figure 1C ). The presence of homozygosity strongly suggested a recessive causative gene, and the lack of overlap with known NS gene loci suggested that the gene to be identified in this family would be novel. By WER in one of the affected siblings from family A2338, we detected a homozygous missense mutation (c.532C>T;p.R178W) in ADCK4 (NM_024876.3) on chromosome 19, encoding ADCK4. This variant was the only homozygous variant remaining from the variant filtering process (Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/JCI69000DS1). The mutation (p.R178W) alters an amino acid residue conserved throughout evolution from Chlamydomonas reinhardtii. It segregated with the affected status in this family and was absent from >190 ethnically matched healthy control individuals and from >8,600 European controls in the Exome Variant Server (http://evs.gs.washington.edu/EVS/). WER in an addtional 6 different families with SRNS also yielded 9 additional mutations in ADCK4 (3 families with homozygous mutations and 3 families with compound heterozygous mutations) (Figure 1 , D-G, and Table 1 ). WER of one affected individual in family 386 identified compound heterozygous mutations: c.101G>A;p.W34* and c.954_956dup;p.T319dup. We identified compound heterozygous mutations (c.645delT;p.F215Lfs*14 and c.4130G>A;p.R477Q in ADCK4) in 2 affected siblings from family 231 from Algeria ( Figure 1F and Table 1 ). The missense mutation (p.R477Q) altered an amino acid residue that was continually conserved from C. reinhardtii to humans ( Figure 1G ). In a family (A5170) of 3 affected siblings, WER revealed compound heterozygous mutations: c.857A>G;p.D286G and c.1447G>T;p.E483* in ADCK4 ( Figure 1F and Table 1 ). This missense mutation (p.D286G) altered an amino acid residue that is continually conserved from C. reinhardtii to humans ( Figure 1G ). One of the homozygous mutations (p.R320W) in ADCK4 was found in 2 affected siblings from the ABD family from Tunisia in an amino acid residue continually conserved throughout evolution from C. reinhardtii (Figure 1 , F and G, and Table 1 ). In another family (Mek) from Morocco, we discovered a missense mutation c.1027C>T;p.R343W in this gene in 2 affected siblings ( Figure 1F and Table 1 ). The amino acid residue R343 has been conserved from C. reinhardtii to humans ( Figure 1G ). The other homozygous mutation was an out-of-frame deletion of 7 bases (p.Q452Hfs) in exon 15 of ADCK4 in 2 affected siblings from a family from India, with renal histology showing collapsing FSGS (cFSGS) ( Figure 1F and Table 1) .
To discover additional mutations in ADCK4, we then performed multiplex barcoded array-based PCR amplification and next-generation sequencing in an additional 400 individuals with SRNS (10) . In an individual with SRNS (A4169-21), we detected a homozygous insertion of an "A" (H400Nfs*11) in exon 13 of ADCK4 ( Figure 1F and Table 1 ). Sequences of primers used to amplify exons and exon-intron boundaries of ADCK4 are listed in Supplemental Table 2 . All 15 affected individuals of the 8 families with recessive mutations in ADCK4 had SRNS. Renal biopsy revealed FSGS in most cases. Interestingly, in 3 affected individuals (1146, Pt5497, and Pt5497), renal histology showed cFSGS ( Figure 1B and Table 1 ). Moreover, the individual A4169-21, who has a homozygous truncating allele, showed the earliest onset of SRNS and also presented with developmental delay (Table 1) .
ADCK4 spans 12 kb on chromosome 19q13.1. Up to 17 different putative alternatively spliced ADCK4 transcripts encoding different proteins have been proposed (AceView; http://www.ncbi. nlm.nih.gov/ieb/research/acembly/index.html). The longest transcript of ADCK4 (NM_024876.3) has 14 coding exons ( Figure 1D ) and encodes a 60.1-kDa protein (NP_079152.3, isoform a, 544 
Table 1
Recessive ADCK4 mutations detected in individuals with SRNS amino acids) ( Figure 1E ). Analysis of the ADCK4 amino acid sequence yielded a helical domain and an ABC1 domain and a kinase domain ( Figure 1E ). ADCK4 has high sequence similarity to Abc1/Coq8 and is evolutionarily conserved to Ciona intestinalis (sea squirt) (XP_002126787.1), Drosophila melanogaster (NP_572836.1), Caenorhabditis elegans (NP_498014.2), C. reinhardtii (XP_001702520.1), and Saccharomyces cerevisiae (NP_011396.1), suggesting a conserved function of the domain assembly. Knockdown of adck4 in animal models recapitulates the nephrosis phenotype. To further validate the causative role of ADCK4 for the SRNS phenotype, we performed knockdown of the ADCK4 ortholog in zebrafish. For zebrafish gene knockdown experiments, we used a p53 morpholino oligonucleotide (MO) as a negative control to minimize nonspecific apoptotic MO effects (11) . p53 MO injection into fertilized zebrafish eggs at the 1-to 4-cell stage did not produce any phenotype through 168 hours postfertilization (hpf) (Figure 2A ). However, coinjection of the p53 control MO with an MO targeting the translation initiation site of zebrafish adck4 caused the nephrosis phenotype of periorbital and total body edema, reminiscent of signs of NS in humans, in 54.1% of embryos at 120 hpf ( Figure 2B ). Similar results were obtained with 2 MOs targeting the splice donor site (e2i2 MO and e3i3 MO) ( Figure 2C Table 3 ). The summary of edema phenotype observed in adck4 morphants is displayed in Supplemental Figure 1E . The proteinuric effect of the adck4 MO was confirmed using an established zebrafish proteinuria assay (12) by ELISA against a fusion protein of vitamin D-binding protein and GFP in l-fabp::VDBP-GFP transgenic zebrafish ( Figure 2D ). We then performed transmission electron microscopy imaging of zebrafish to permit a more direct evaluation of glomerular structures of morphants. When compared with the control (Figure 2E ), we observed upon knockdown of adck4 characteristic alterations of nephrosis ( Figure 2E ). These included podocyte foot process effacement and disorganization, rarefaction of slit membranes, and disorganization of the glomerular basement membranes in zebrafish glomeruli ( Figure 2E , black arrowheads in right panel), as previously described in plce1 knockdown (13) .
In addition, we performed knockdown of Drosophila coq8 (dcoq8) in Drosophila pericardial nephrocytes, which share remarkable similarities to the glomerular podocytes (14) . The protein uptake assay showed that knockdown of dcoq8 in nephrocytes reduced the uptake ability of a secreted fusion protein of rat atrial natriuretic factor (ANF) and GFP, suggesting that dcoq8 is required for nephrocyte function in Drosophila (Supplemental Figure 2 , A and B). The amino acid of dCoq8 has 53% sequence identity to both ADCK3 and ADCK4 Drosophila (Supplemental Figure 2C) .
ADCK4 localizes to the mitochondria and foot processes in podocytes. Since most gene products that are defective in SRNS are located in glomerular podocytes, we examined the subcellular localization of ADCK4 in adult rat kidney by immunofluorescence (IF). Podocytes, as identified by expression of nuclear WT1, expressed ADCK4 at high levels in cell bodies and primary processes ( Figure 3A ). ADCK4 also partially colocalized with cytochrome oxidase subunit VI (COXIV) and mitochondrially encoded cytochrome c oxidase 1 (MTCO1), 2 known mitochondrial marker proteins, suggesting that ADCK4 partly localizes to the mitochondria in renal glomeruli ( Figure 3 , B and C). In addition, ADCK4 is detected in proximal tubules and collecting ducts (Supplemental Figure 3 , A and B). To further investigate the localization of ADCK4, we performed immunogold electron microscopy in adult rat kidneys. In podocytes, ADCK4 was predominantly detected at foot processes ( Figure 3D ). The specificity of the anti-ADCK4 antibody used in the IF and immunogold electron microscopy studies is demonstrated in Supplemental Figure 4 . We also examined the expression of ADCK4 in cultured podocytes by IF. The overexpressed ADCK4-red fluorescent protein (ADCK4-RFP) partially colocalized to mitochondria, and we also noticed that ADCK4-RFP localized to ruffles ( Figure 3E ) of podocytes, the equivalents of foot processes ( Figure 3E and Supplemental Figure 3 , C and D). Consistent with data from the cellular fractionation of cultured podocytes, these findings showed that ADCK4 is endogenously present in both the cytosolic and mitochondrial fractions ( Figure 3F ). Thus, in addition to its role in the mitochondrial respiratory chain, ADCK4 seems to have a very localized function at ruffles and foot processes of podocytes.
ADCK4 is enriched in podocytes and interacts with COQ6 and COQ7. By quantitative real-time PCR, we showed that, although ADCK3 expression exceeds that of ADCK4 in most human tissues (Supplemental Figure 5 ), ADCK4 is enriched in both differentiated and undifferentiated human podocytes ( Figure 4A ). Furthermore, we performed coimmunoprecipitation studies in cultured podocytes to examine whether ADCK4 interacts with other proteins like COQ6 and COQ7 that are involved in the coenzyme Q 10 (CoQ 10 ) biosynthesis pathway. COQ6 was overexpressed in podocytes, and coimmunoprecipitation was performed. Interestingly, the protein complex precipitated by COQ6 included COQ7 and ADCK4 ( Figure 4B ). We also confirmed that ADCK4 and COQ6 interact endogenously in lysates from differentiated podocytes ( Figure 4C ).
Levels of CoQ 10 are decreased in individuals with ADCK4 mutations. To investigate whether the defect in ADCK4 has any effect on CoQ 10 biosynthesis, we measured the total CoQ 10 contents in EBV-transformed lymphoblasts or cultured skin fibroblasts derived from individuals from the A2338, A4169, and Pt5496/Pt5497 families, in which ADCK4 mutations were detected. In the case of the A2338 and A4169 families, the total CoQ 10 was found to be strongly reduced in the affected siblings, A2338-21 (81.92 ± 18.45 pmol/mg protein) and A2338-22 (75.99 ± 34.60 pmol/mg protein), who have a homozygous missense mutation (p.R178W), and in an affected individual, A4169-21 (59.12 ± 9.57 pmol/mg protein), who has a homozygous frameshift mutation (p.H400Nfs*11) ( Figure 5A ). In contrast, the unaffected individuals, A2338-26 and A2338-27, who have both wild-type alleles, had 784.40 ± 164.10 and 758.00 ± 286.60 pmol/mg protein of total CoQ 10 , respectively ( Figure 5A) .
Likewise, in the case of Pt5496 and Pt5497, we confirmed similar results and found that the total CoQ 10 was reduced in fibroblasts (20.11 ± 3.41 pmol/mg protein for #50552 and 19.75 ± 4.63 pmol/mg protein for #50553) from these individuals, who have a homozygous frameshift mutation (p.Q452Hfs), and normal in fibroblasts (64.33 ± 11.92 pmol/mg protein for #50551 and 83.04 ± 20.64 pmol/mg protein for #50550) from the unaffected parents ( Figure 5B ).
In addition, we examined mitochondrial respiratory enzyme activity in fibroblasts by measuring maximal uncoupled oxygen consumption rate (OCR), which shows the CoQ 10 transfer of electrons from mitochondrial complex I and complex II to complex III. Maximal OCR was significantly reduced in fibroblasts from Pt5496 and Pt5497 compared with that in fibroblasts from controls or their healthy parents ( Figure 5C ).
Loss of ADCK4 does not induce proliferation or apoptosis in fibroblasts or cultured podocytes. We had previously reported that knockdown of COQ6 can cause apoptosis in podocytes (7) . Since ADCK4 interacts with COQ6, we investigated the effect of loss of ADCK4 on cell proliferation and apoptosis in fibroblasts from individuals with a homozygous frameshift ADCK4 mutation (Pt5496 and Pt5497) and their healthy parents as well as in cultured podocytes. We found that fibroblasts (#50552 and #50553) from affected individuals did not show any difference in cell proliferation or apoptosis induced by hydrogen peroxide compared to parental fibroblasts (#50550 and #50551) (Supplemental Figure 6, A and B ). Furthermore, in contrast to COQ6, knockdown of ADCK4 in podocytes did not affect proliferation or apoptosis (Supplemental Figure 6 , C and D).
ADCK4 knockdown reduces podocyte migration, which is reversed by the addition of CoQ 10 . We next examined the effect of ADCK4 knockdown on podocyte migration using the xCELLigence system, which monitors cell migration in real-time ( Figure 6 ). We found that migration of podocytes was reduced by knockdown of ADCK4 ( Figure 6A ). Because CoQ 10 treatment had resulted in improvement of the NS phenotype in an individual with a mutation in ADCK4, we tested the effect of the addition of CoQ 10 on podocyte migration. Interestingly, we found that the addition of CoQ 10 reversed the decreased migratory phenotype caused by ADCK4 knockdown (Figure 6, A and B) . Similar results were obtained when 2 additional siRNAs were used for knockdown of ADCK4 in cultured human podocytes (ADCK4 siRNAs #5 and #6) ( Figure 6, C and D) . We further found that decreased migration, which was caused by an ADCK4 siRNA (ADCK4 siRNA #6), was reversed when wild-type mouse ADCK4 was transfected into podocytes ( Figure 6C ). This result also confirmed that the effect on podocyte migration was caused by ADCK4 loss of function.
Discussion
Here, we describe the discovery of mutations in ADCK4 as causes of SRNS. We have shown that ADCK4 is expressed in podocytes and localizes to mitochondria and foot processes and interacts with COQ6 endogenously. Knockdown of ADCK4 in podocytes reduced their migration phenotype, which could be reversed by overexpression of siRNA-resistant ADCK4 or, most importantly, by the addition of CoQ 10 . By knockdown of adck4 in zebrafish, we clearly demonstrated that the function of this gene is necessary to avoid the NS disease phenotype. The fact that ADCK4 has high sequence similarity with ADCK3, which was previously reported to be associated with CoQ 10 deficiency (15) , and the fact that cells from affected individuals with ADCK4 mutations (families A2338, A4169, and Pt5496/Pt5497) had reduced total CoQ 10 content suggests that ADCK4 is also involved in CoQ 10 biosynthesis.
CoQ 10 , also known as ubiquinone, is a lipid-soluble component of virtually all cell membranes, in which it is thought to play an important antioxidant role as well as to transport electrons from complexes I and II to complex III in the respiratory chain of the mitochondrial inner membrane (16) . The biochemical pathway of CoQ 10 biosynthesis is complex and has not been completely elucidated. Primary CoQ 10 deficiencies due to mutations in ubiquinone biosynthetic genes (COQ2, COQ4, COQ6, PDSS1, PDSS2, and ADCK3) have been identified (7, 15, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Clinical manifestations of CoQ 10 deficiency are variable. For example, individuals with COQ2 mutations present with phenotypes ranging from isolated NS to catastrophic neonatal multisystem disorder with encephalomyopathy and renal involvement to a recently described multiple-system atrophy (20, (23) (24) (25) (26) (27) . In Coimmunoprecipitation was performed using an anti-V5 antibody and then blotting was performed with antibodies for ADCK4, COQ6, and COQ7. Note that the protein complex precipitated by COQ6 includes COQ7 and ADCK4. (C) Interaction of endogenous ADCK4 and COQ6 in differentiated podocytes. Podocyte lysates were precipitated with an anti-ADCK4 antibody or a control rabbit IgG. The precipitated proteins were separated by SDS-PAGE and blotted with an anti-COQ6 antibody.
addition, COQ6 (7) and PDSS2 (19) have also been implicated in the cause of SRNS.
We as well as Montini et al. have shown previously that the individuals affected with SRNS due to mutations in CoQ 10 biosynthesis pathway genes like COQ2 and COQ6 can be treated with the innocuous food supplement CoQ 10 (7, 28) . CoQ 10 deficiency in individuals with ADCK4 mutations thus raises the possibility of supplementation therapy. So far, only one individual (A4169-21) with ADCK4 mutation has been treated with CoQ 10 (15 mg/kg/d) for over 4 years. He was first treated with intravenous methylprednisolone followed by 2 mg/kg/d prednisolone over 10 weeks without achieving remission of NS. Subsequently, he was treated with 2 mg/kg/d cyclophosphamide for 3 months. The treatment resulted in partial remission, but treatment had to be stopped because of infections. Treatment with CoQ 10 was commenced at 1 year of age, giving 100 mg/d CoQ 10 orally together with 5 mg of prednisolone every other day. Then, the edema disappeared and proteinuria decreased significantly. The individual is currently being treated with CoQ 10 (15 mg/kg/d) with captopril (12.5 mg/d). Even though the effectiveness of CoQ 10 treatment cannot be generalized for individuals with ADCK4 mutations at the moment based on this single case, we still think that the identification of molecular defects of CoQ 10 biosynthesis is important because they may represent forms of SRNS that are treatable by administration of CoQ 10 .
ADCK3 and ADCK4 are highly similar members of an ancient atypical kinase family and appear to result from gene duplication in vertebrates (15) . The yeast Coq8/Abc1 is required for CoQ biosynthesis (29) and is essential for the organization of high-molecular-mass Coq polypeptide complex and for phosphorylated forms of the Coq3, Coq5, and Coq7 polypeptides that perform methylation and hydroxylation steps in CoQ biosynthesis (30, 31) . Con-sidering their similarity, it is interesting that mutations in ADCK3 result in cerebellar ataxia and seizures without renal involvement (15, 21) , whereas mutations in ADCK4 cause SRNS mostly without neurological symptoms. Currently, there is no clear explanation for this; however, this may be partially due to their differential tissue expression ( Figure 4A and Supplemental Figure 5 ). Xie et al. previously showed that ADCK3 can rescue yeast coq8 mutants and restore phosphorylated forms of yeast Coq polypeptides (30), but the same group observed that expression of ADCK4 failed to rescue coq8 mutants (data not shown). On the other hand, knockdown of Dcoq8, which has 53% amino acid identity to both ADCK3 and ADCK4, caused defects in nephrocyte function (Supplemental Figure 2 ). Overall, these results suggest that ADCK3 and ADCK4 are independently required for synthesis of CoQ, yet retain distinct functions, a difference that may have evolved in vertebrates, and that ADCK3 may be closer to yeast Coq8. cFSGS is defined morphologically by the presence of hyperplastic and hypertropic podocytes overlying collapsed capillary loops within glomerular tufts (32) . Interestingly, the histology of affected individuals (1146, Pt5496, and Pt5497) with ADCK4 mutations showed cFSGS. In addition, mutant kd/kd mice, which have a missense mutation in Pdss2 and present with isolated nephropathy, have features of cFSGS (33) . Therefore, it will be important to investigate whether nephropathy resulting from CoQ 10 deficiency results in cFSGS, because this may be a phenotypic criterion with which to choose individuals with SRNS that should be screened for genes involved in CoQ 10 biosynthesis, such as COQ2, COQ6, PDSS2, and ADCK4. To answer this, it is necessary to investigate more SRNS cases resulting from CoQ 10 deficiency. In addition, knockout animal models for Coq2, Coq6, and Adck4 will be helpful. In conclusion, we identified recessive mutations in ADCK4 as novel single-gene causes of SRNS. Early recognition of this new genetic entity of SRNS will be important because it may represent a form of SRNS that can potentially be treated by CoQ 10 supplementation.
Methods
Subjects. Following informed consent, we obtained clinical data and blood samples from individuals with SRNS or steroid-sensitive NS from worldwide sources. The diagnosis of NS was made by (pediatric) nephrologists based on standardized clinical and renal histological criteria (34) . Renal biopsies were evaluated by renal pathologists. Clinical data were obtained using a standardized questionnaire (http://www.renalgenes.org).
HM, WER, and mutation calling. For the A2338 family, HM, WER, and mutation calling were performed as described previously (35) . HM in the 231 and ABD families was performed using Human Mapping 250k NspI Array (Affymetrix), and parametric logarithm of odds (LOD) scores were calculated with MERLIN (36) . For WER of the 231, ABD, and Mek families, DNA was processed using All Exon 50Mb V3 (Agilent SureSelect) to enrich for exonic sequences and a SOLiD 5500XL high-throughput sequencing machine (Applied Biosystems) (paired-end reads: 50 bases forward, 25 bases reverse). Obtained sequences were aligned to the human genome (NCBI build 37/hg19) using Lifescope suite from Lifetech. Substitution and variation calls were made with the GATK pipeline (mpileup, bfctools, vcfuitil). Variants were then annotated with an in-house software (Polyweb), which allows users to set up bioinformatic filters in order to identify the putative mutation.
Plasmids, cell culture, and transfection. A human ADCK4 clone was purchased from Open Biosystems (clone accession BC013114.1). The mutant clones of ADCK4 were generated by a PCR-based site-directed mutagenesis method. The COQ6 clones were described previously (7) . The immortalized human podocytes (37) were maintained in RPMI plus GlutaMAX-I (Gibco) supplemented with 10% FBS, penicillin (50 IU/ml)/streptomycin (50 μg/ml), and Insulin-Transferrin-Selenium-X (Invitrogen). Plasmids and siRNA were transfected into podocytes using Lipofectamine 2000 (Invitrogen). The ADCK4-specific and control scrambled siRNAs were purchased from Dharmacon or Sigma-Aldrich. Lymphoblasts were purified from blood samples using Ficoll-Paque PLUS (GE Healthcare) according to the manufacturer's instructions. The isolated lymphoblasts were transformed by EBV and immortalized as described previously (38) . Human fibroblasts were grown in DMEM supplemented with 15% FBS, penicillin (50 IU/ml)/ streptomycin (50 μg/ml), and nonessential amino acids (Invitrogen).
Immunoblotting, immunoprecipitation, and IF staining. These experiments were performed as described previously (13) . Anti-ADCK4 (LSBio), anti-MTCO1 (Abcam), anti-COXIV (Abcam), anti-COQ6 (Santa Cruz Biotechnology Inc.), anti-COQ7 (Proteintech), and anti-V5 (Invitrogen) were used. Fluorescent images were obtained with a Leica SP5X laser scanning microscope.
Immunogold electron microscopy. Rat renal cortex samples were dissected and trimmed into 1-mm-thick blocks, which were fixed by immersion in 4% formaldehyde and 0.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, and processed for embedment in LR White. Semithin sections (700 nm) were first obtained to locate areas that contained glomeruli. Subsequently, ultrathin sections (70 nm) were obtained from those areas and collected on formvar-coated nickel grids and etched with saturated sodium periodate for 15 minutes. Sections were blocked with 0.1 M phosphate buffer, pH 7.4, containing 1% BSA, 3% goat serum, and 0.05% Tween-20 for 1 hour at room temperature and incubated with a rabbit anti-ADCK4 antibody (LSBio) in buffer overnight at 4°C. Sections were then washed and incubated with goat anti-rabbit IgG conjugated to 18 nm gold (Jackson ImmunoResearch Laboratories) and stained with uranyl acetate. Sections in which the primary antibody was omitted during the overnight incubation were used as negative control. Sections were observed on a Zeiss 910 transmission electron microscope.
Mitochondrial fractionation. The mitochondrial fractionation of podocytes was done using Mitochondrial Isolation Kit for Cultured Cells (Thermo Scientific), Mitochondrial/Cytosol Fractionation Kit (Abcam), and Mitochondrial Fractionation Kit (Active Motif) according to the manufacturer's instructions.
Figure 6
Knockdown of ADCK4 decreases the migratory phenotype of podocytes. (A) The effect of ADCK4 knockdown on podocyte migration. Podocytes transfected with ADCK4 siRNA (red) exhibited decreased migration compared with podocytes transfected with scrambled siRNA (black). The decrease in podocyte migration was partially reversed by the addition of 50 μM CoQ10 (green). Error bars are shown in only one direction for clarity and indicate SDs from 3 independent experiments. (B) The efficiency of ADCK4 siRNA used in A was confirmed by immunoblotting with an anti-ADCK4 antibody and an anti-β-actin antibody. (C) Transfection of podocytes with 2 additional ADCK4-specific siRNAs (siRNA #5 and #6) confirmed the result from A that ADCK4 knockdown in human podocytes reduces migration (red dotted and solid lines) compared with podocytes transfected with the scrambled siRNA (black). The decrease in podocyte migration by ADCK4 knockdown using ADCK4 siRNA #6 was rescued by transfection of mouse Adck4 construct (green). Mouse ADCK4 has 5 mismatches from the siRNA target sequences.
Error bars indicate SDs of 3 independent experiments. (D) The efficiency of ADCK4 siRNAs used in C was confirmed by immunoblotting. 100 nM of each siRNA was transfected into podocytes. and UAS-RNAi transgenes (14, 41) . Nephrocyte function was measured by the amount of secreted red fluorescent proteins accumulated in nephrocytes at the second instar larvae stage (14, 41) . Hand-GFP (42) was used to label the cardiac nephrocytes.
Statistics. Results are presented as mean ± SEM or SD for the number of experiments indicated in the figure legends. Statistical analysis of continuous data was performed with 2-tailed Student's t test or multiple comparison, as appropriate. P < 0.05 was considered statistically significant.
Study approval. Approval for research in human subjects was obtained from the IRBs of the University of Michigan, Boston Children's Hospital, Université Paris Descartes, University of Toronto, Yale University, and Beth Israel Deaconess Medical Center.
